Article Text

PDF

PL05.1 PrEP & Treatment as Prevention For HIV: Finding the Balance
  1. J Baeten
  1. University of Washington, Seattle, WA, United States

Abstract

Antiretroviral-based HIV-1 prevention strategies - including antiretroviral treatment (ART) to reduce the infectiousness of HIV-1 infected persons and antiretroviral pre-exposure prophylaxis (PrEP) for uninfected persons to prevent HIV-1 acquisition - are promising new approaches for decreasing HIV-1 spread. The past two years have seen significant new advances in knowledge regarding ART and PrEP for HIV-1 prevention, including definitive demonstration in randomised trials that both ART and PrEP reduce HIV-1 risk and the development of normative guidance for prescribing these HIV-1 prevention strategies. Adherence is key to efficacy of antiretrovirals for HIV-1 prevention, both as ART and PrEP. There are numerous parallels in the challenges and opportunities ahead for ART and PrEP, including how to target to realise maximum population benefits, whether HIV-1 infected persons at earlier stages of infection would accept ART to reduce their risk for transmitting HIV-1 and highest-risk HIV-1 negative persons would use PrEP, whether high adherence could be sustained to achieve high effectiveness, and how to integrate these strategies into HIV-1 prevention programmes. Delivering these strategies in order to achieve population-level benefits is the next step, balancing costs, optimism, and realistic appreciation of the challenges ahead.

  • antiretroviral therapy
  • HIV-1 prevention
  • PrEP

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.